Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 13, 2024
Discovery & Translation
Science spotlight: Tumors siphon taurine from T cells, and Revolution’s RAS (ON) inhibitors
BioCentury’s roundup of translational innovations
BioCentury | Sep 22, 2023
Distillery Therapeutics
Noncovalent inhibitor targeting multiple KRAS mutations in cancer
BioCentury | May 12, 2023
Emerging Company Profile
Vevo: scaling up in vivo discovery of cancer targets
Backed by Wing Venture Capital and General Catalyst, Vevo is modeling many patients’ tumors in single mice
BioCentury | Apr 25, 2023
Product Development
KRAS’s next chapter: hitting the target’s active form
Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic
BioCentury | Jul 9, 2019
Finance
Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos
How Revolution Medicines plans to deploy Boxer Capital-led series C to advance portfolio of Ras pathway inhibitors
Items per page:
1 - 10 of 45